EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

EWS/FLI is a master regulator of Ewing's sarcoma formation. Gene expression studies in A673 Ewing's sarcoma cells have demonstrated that EWS/FLI downregulates more genes than it upregulates, suggesting that EWS/FLI, and/or its targets, function as transcriptional repressors. One critical EWS/FLI target, NKX2.2, is a transcription factor that contains both transcriptional activation and transcriptional repression domains, raising the possibility that it mediates portions of the EWS/FLI transcriptional signature. We now report that microarray analysis demonstrated that the transcriptional profile of NKX2.2 consists solely of downregulated genes, and overlaps with the EWS/FLI downregulated signature, suggesting that NKX2.2 mediates oncogenic transformation via transcriptional repression. Structure-function analysis revealed that the DNA binding and repressor domains in NKX2.2 are required for oncogenesis in Ewing's sarcoma cells, while the transcriptional activation domain is completely dispensable. Furthermore, blockade of TLE or HDAC function, two protein families thought to mediate the repressive function of NKX2.2, inhibited the transformed phenotype and reversed the NKX2.2 transcriptional profile in Ewing's sarcoma cells. Whole genome localization studies (ChIP-chip) revealed that a significant portion of the NKX2.2-repressed gene expression signature was directly mediated by NKX2.2 binding. These data demonstrate that the transcriptional repressive function of NKX2.2 is necessary, and sufficient, for the oncogenic phenotype of Ewing's sarcoma, and suggest a therapeutic approach to this disease.

[1]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  U. Völker,et al.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells , 2007, Journal of Cancer Research and Clinical Oncology.

[3]  J. Fernández,et al.  A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. , 1999, Genes & development.

[4]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[5]  S. Minucci,et al.  Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.

[6]  Q. Wei,et al.  Stage-specific Expression of Myelin Basic Protein in Oligodendrocytes Involves Nkx2.2-mediated Repression That Is Relieved by the Sp1 Transcription Factor* , 2005, Journal of Biological Chemistry.

[7]  Todd R Golub,et al.  Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma , 2007, PLoS medicine.

[8]  D. Shapiro,et al.  The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. , 1995, Oncogene.

[9]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[10]  A. Pappo,et al.  Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. , 2003, Medical and pediatric oncology.

[11]  H. Watada,et al.  Intramolecular control of transcriptional activity by the NK2-specific domain in NK-2 homeodomain proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Golub,et al.  Supplemental Information for , 2002 .

[13]  Michael S. German,et al.  Paired-Homeodomain Transcription Factor PAX4 Acts as a Transcriptional Repressor in Early Pancreatic Development , 1999, Molecular and Cellular Biology.

[14]  S. Bates,et al.  MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. , 2002, Cancer research.

[15]  T. Okamoto,et al.  Inhibition of Nuclear Factor-κB-mediated Transcription by Association with the Amino-terminal Enhancer of Split, a Groucho-related Protein Lacking WD40 Repeats* , 2000, The Journal of Biological Chemistry.

[16]  Y. Iwamoto,et al.  Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.

[17]  L. Lee,et al.  The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. , 1996, Oncogene.

[18]  Thomas M. Jessell,et al.  Groucho-Mediated Transcriptional Repression Establishes Progenitor Cell Pattern and Neuronal Fate in the Ventral Neural Tube , 2001, Cell.

[19]  L. Sussel,et al.  Nkx2.2-repressor activity is sufficient to specify α-cells and a small number of β-cells in the pancreatic islet , 2006 .

[20]  L. Thompson.  Ewing Sarcoma and Primitive Neuroectodermal Tumor , 2007, Ear, nose, & throat journal.

[21]  J. Thiery,et al.  Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). , 1988, Cancer genetics and cytogenetics.

[22]  T. Golub,et al.  Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. , 2006, Cancer cell.

[23]  S. Lessnick,et al.  NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma , 2006, Molecular Cancer Research.

[24]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[25]  C. Denny,et al.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.

[26]  M S German,et al.  Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. , 1998, Development.

[27]  S. Lessnick,et al.  Identification of Target Genes in Their Native Cellular Context , 2006, Cell cycle.

[28]  H. Grier.  The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. , 1997, Pediatric clinics of North America.

[29]  C. Denny,et al.  Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. , 1995, Oncogene.

[30]  L. Sussel,et al.  Nkx2.2-repressor activity is sufficient to specify alpha-cells and a small number of beta-cells in the pancreatic islet. , 2007, Development.

[31]  A. Zelent,et al.  Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. , 1998, Blood.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Peter C. Hollenhorst,et al.  Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. , 2007, Genes & development.

[34]  M. Ouchida,et al.  TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. , 1994, Oncogene.

[35]  J. Rubenstein,et al.  Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling , 1999, Nature.

[36]  S. Lessnick,et al.  The Potential for molecular therapeutic targets in Ewing’s sarcoma , 2005, Current treatment options in oncology.

[37]  P. Couvreur,et al.  EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. , 2000, Biochemical and biophysical research communications.

[38]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.